SAN DIEGO–(BUSINESS WIRE)–Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular, immunological and fibrotic diseases, today announced outcomes from its Type C meeting with the Food and Drug Administration (FDA). Epirium has received written feedback from the FDA on its Phase 2b trial plan to evaluate MF-300, an oral 15-PGDH enzyme inhibitor for the treatment of age-related sarcopenia. Epirium has previously completed a positive Phase 1 cl
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
